In conclusion, these preliminary data suggest that histone methyltransferases are promising targets for the therapeutic management of CCA, and that epigenetic markers may hold great clinical potential as diagnostic biomarkers in this entity. Here, PRDM9 is linked to cholangiocarcinoma.